TriangleNCT00602667 · OUTCOME
Percent of PET Scans With Loss of Signal Intensity
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- mean activation value (MAV)
- Interval / dispersion
- Standard Deviation
- Time frame
- Up to 3 times during RT consolidation
What was measured
Measures will be analyzed for intermediate risk participants who receive proton beam therapy (PBT) and who consent. This objective aims to assess the feasibility of using post-proton beam therapy (PBT) positron emission tomography (PET) as an in-vivo dosimetric and distal edge verification system in this patient population. To quantify the decay in signal, 134 scans from 53 patients were analyzed by recording the mean activation value (MAV), the average recorded PET signal from activation, within the target volume. With each patient being given the same dose, the percent standard deviation in the MAV can serve as a quantitative representation of signal loss due to radioactive decay.
Analysis population: Intermediate risk patients treated at St. Jude were eligible to receive proton beam therapy through referral to the University of Florida Proton Therapy Institute. Patients electing to receive PBT and post-treatment PET scans after the delivery of one treatment beam were included in the analysis.
Groups in this outcome
Intermediate Risk Group
Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease
| Group | Source count |
|---|---|
| Intermediate Risk Group | 53 |
| Group | Source count |
|---|---|
| Intermediate Risk Group | 134 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Intermediate Risk Group | 60 | 27 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 27
- value
- 60
- denom Units Selected
- Scans
- denoms
- counts
- group Id
- OG000
- value
- 53
- units
- Participants
- counts
- group Id
- OG000
- value
- 134
- units
- Scans
- description
- Measures will be analyzed for intermediate risk participants who receive proton beam therapy (PBT) and who consent. This objective aims to assess the feasibility of using post-proton beam therapy (PBT) positron emission tomography (PET) as an in-vivo dosimetric and distal edge verification system in this patient population. To quantify the decay in signal, 134 scans from 53 patients were analyzed by recording the mean activation value (MAV), the average recorded PET signal from activation, within the target volume. With each patient being given the same dose, the percent standard deviation in the MAV can serve as a quantitative representation of signal loss due to radioactive decay.
- dispersion Type
- Standard Deviation
- groups
- description
- Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease
- id
- OG000
- title
- Intermediate Risk Group
- param Type
- MEAN
- population Description
- Intermediate risk patients treated at St. Jude were eligible to receive proton beam therapy through referral to the University of Florida Proton Therapy Institute. Patients electing to receive PBT and post-treatment PET scans after the delivery of one treatment beam were included in the analysis.
- reporting Status
- POSTED
- time Frame
- Up to 3 times during RT consolidation
- title
- Percent of PET Scans With Loss of Signal Intensity
- type
- SECONDARY
- type Units Analyzed
- Scans
- unit Of Measure
- mean activation value (MAV)
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice